tg
therapeutics
announces
data
presentations
upcoming
american
society
hematology
annual
meeting
exposition
new
york
globe
newswire
tg
therapeutics
nasdaq
tgtx
today
announced
four
abstracts
accepted
presentation
upcoming
american
society
hematology
ash
annual
meeting
exposition
held
virtually
december
abstracts
made
publicly
available
online
november
et
via
ash
meeting
website
company
also
host
zoom
conference
call
leading
investigators
trials
thursday
november
beginning
et
details
ash
presentations
conference
call
outlined
michael
weiss
executive
chairman
chief
executive
officer
stated
excited
four
abstracts
accepted
presentation
upcoming
ash
conference
highlighting
data
two
registration
directed
trials
phase
trial
ublituximab
combination
umbralisib
cll
mzl
fl
sll
umbralisib
monotherapy
cohorts
nda
umbralisib
monotherapy
previously
treated
mzl
fl
currently
review
actively
preparing
bla
nda
submission
combination
cll
submitted
coming
months
based
results
phase
study
demonstrating
potential
build
upon
backbone
regimens
also
two
triple
therapy
datasets
presented
one
plus
btk
inhibitor
one
plus
venetoclax
cll
look
forward
abstracts
released
publicly
november
et
reviewing
exciting
data
conference
call
ash
presenta
ion
details
oral
presentation
title
umbralisib
plus
ublituximab
superior
obinutuzumab
plus
chlorambucil
patients
treatment
naïve
tn
relapsed
refractory
r
r
chronic
lymphocytic
leukemia
cll
results
phase
study
publication
number
oral
session
cll
therapy
excluding
transplantation
session
date
time
monday
december
pacific
time
presentation
time
pacific
time
presenter
john
gribben
north
east
london
cancer
research
network
centre
barts
london
cancer
center
uk
poster
presentation
title
umbralisib
daily
dual
inhibitor
casein
demonstrates
clinical
activity
patients
relapsed
refractory
indolent
lymphoma
results
phase
global
trial
publication
number
session
mantle
cell
follicular
indolent
studies
poster
iii
date
time
monday
december
pm
pacific
time
presenter
pier
luigi
zinzani
md
institute
hematology
l
e
seràgnoli
university
bologna
italy
poster
presentation
title
phase
study
umbralisib
ublituximab
venetoclax
patients
relapsed
refractory
chronic
lymphocytic
leukemia
cll
publication
number
session
cll
therapy
excluding
transplantation
poster
iii
date
time
monday
december
pm
pacific
time
presenter
paul
barr
md
wilmot
cancer
institute
university
rochester
medical
center
ny
poster
presentation
title
clinical
activity
monotherapy
combination
ublituximab
umbralisib
patients
malignancies
publication
number
session
mantle
cell
follicular
indolent
studies
poster
date
time
saturday
december
pm
pacific
time
presenter
chan
cheah
md
sir
charles
gairdner
hospital
hollywood
private
hospital
university
western
australia
blood
cancer
research
western
australia
abstracts
made
publicly
available
online
november
et
via
ash
meeting
website
also
accessible
via
publications
page
tg
corporate
website
http
following
presentation
ash
data
presented
also
available
tg
website
zoom
confer
ence
call
information
company
host
zoom
conference
call
november
et
order
participate
call
please
join
via
zoom
webinar
link
https
also
available
events
page
located
within
investors
media
section
company
website
https
events
attendees
may
also
join
via
phone
dialing
outside
conference
title
tg
therapeutics
ash
abstract
review
call
recording
conference
call
also
available
replay
period
days
call
tg
therapeutics
tg
therapeutics
biopharmaceutical
company
focused
acquisition
development
commercialization
novel
treatments
malignancies
autoimmune
diseases
currently
company
late
stage
clinical
development
two
investigational
compounds
ublituximab
umbralisib
combination
referred
targeting
hematological
malignancies
autoimmune
diseases
ublituximab
glycoengineered
monoclonal
antibody
targets
specific
unique
epitope
antigen
found
mature
umbralisib
oral
dual
inhibitor
umbralisib
currently
review
food
drug
administration
fda
accelerated
approval
treatment
patients
previously
treated
marginal
zone
lymphoma
mzl
received
least
one
prior
based
regimen
follicular
lymphoma
fl
received
least
two
prior
systemic
therapies
company
also
fully
enrolled
phase
clinical
trial
evaluating
patients
treatment
naïve
relapsed
refractory
chronic
lymphocytic
leukemia
cll
two
fully
enrolled
identical
phase
trials
evaluating
ublituximab
monotherapy
patients
relapsing
forms
multiple
sclerosis
rms
additionally
company
recently
brought
phase
clinical
development
monoclonal
antibody
cosibelimab
bruton
tyrosine
kinase
btk
inhibitor
well
bispecific
antibody
tg
therapeutics
headquartered
new
york
city
cautionary
statement
press
release
contains
statements
involve
number
risks
uncertainties
statements
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
addition
risk
factors
identified
time
time
reports
filed
securities
exchange
commission
factors
could
cause
actual
results
differ
materially
include
following
risk
results
trial
sufficient
acceptable
support
regulatory
submission
combination
ublituximab
umbralisib
treatment
cll
risk
results
trial
previously
treated
fl
mzl
sufficient
support
accelerated
approval
pending
nda
umbralisib
risk
able
meet
regulatory
submission
timelines
project
achieve
anticipated
milestones
including
risk
evolving
unpredictable
pandemic
delays
achievement
milestones
risk
interim
early
clinical
trial
results
may
supported
acceptance
data
presentation
influenced
decision
proceed
additional
clinical
trials
reproduced
final
data
sets
future
studies
risk
combination
prove
safe
efficacious
combination
backbone
triple
therapy
combinations
including
venetoclax
statements
set
forth
press
release
speak
date
press
release
undertake
update
statements
reflect
events
circumstances
occur
date
hereof
press
release
prior
releases
available
information
found
website
incorporated
reference
press
release
included
reference
purposes
contact
jenna
bosco
senior
vice
president
corporate
communications
tg
therapeutics
telephone
email
ir
